Atenolol's Narrative Analysis

560 Words2 Pages

In 1976 a pharmaceutical beta blocker named Atenolol (a synthetic derivative of isopropylamino-propanol) was discovered and developed by the Imperial Chemical Industries (ICI) to treat common cardiovascular disorders (6). To fully understand Atenolol one must first recognize that it is specifically a beta-1 adrenoceptors antagonist. This is crucial because beta blockers follow strict classification guidelines in regards to the specific receptors they will interact with. These receptors are known as β1 adrenoceptors and β2 adrenoceptors, and when a drug (like Atenolol) is found to interact with only β1 adrenoceptors it is called cardioselective while drugs affecting both β1 adrenoceptors and β2 adrenoceptors are known as non-cardioselective. This differentiation between cardioselective versus non-cardioselective allows Atenolol to treat a variety of cardiovascular disorders such as antihypertensive, hypotensive and antiarrhythmic by interacting specifically with the beta-1 adrenergic receptors (7). Atenolol is special when talking about β1 adrenoceptors antagonists because it has the lowest lipid solubility without affecting intrinsic sympathomimetic activity aka ISA (8).

Open Document